Open Access<p>FOXC2 Promotes Oxaliplatin Resistance by Inducing Epithelial-Mesenchymal Transition via MAPK/ERK Signaling in Colorectal Cancer</p>
Author(s) -
Yihong Chen,
Geng Deng,
Yukui Fu,
Ying Han,
Cao Guo,
Ling Yin,
Changjing Cai,
Hong Shen,
Shaobin Wu,
Shan Zeng
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s241367
Subject(s) - epithelial–mesenchymal transition , mapk/erk pathway , cancer research , oxaliplatin , gene knockdown , downregulation and upregulation , chemistry , signal transduction , colorectal cancer , microbiology and biotechnology , biology , medicine , cancer , apoptosis , biochemistry , gene
Chemoresistance is a major obstacle to improving the survival rate of colorectal cancer (CRC) patients. Forkhead box protein C2 (FOXC2), a member of the forkhead box (Fox) transcription factor family, is reported to be an important regulator of epithelial-to-mesenchymal transition (EMT) and plays a key role in tumor progression. However, little is known about the effects of FOXC2 on oxaliplatin (OXA) resistance in CRC.